Log In
BCIQ
Print this Print this
 

SugarDown (BTI-320, BTI320) (formerly PAZ320)

  Manage Alerts
Collapse Summary General Information
Company Boston Therapeutics Inc.
DescriptionChewable non-systemic alpha glucosidase inhibitor
Molecular Target Acid alpha glucosidase (GAA)
Mechanism of ActionAlpha glucosidase inhibitor
Therapeutic ModalityMacromolecule: Polysaccharide
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetes
Indication DetailsTreat patients with high-risk prediabetes; Treat Type II diabetes
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today